Eupraxia Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022
Selling, General & Admin	7.28	3.99
Research & Development	20.56	13.63
Operating Expenses	27.85	17.62
Operating Income	-27.85	-17.62
Interest Expense / Income	1.17	0.98
Other Expense / Income	-0.09	0.39
Pretax Income	-28.93	-18.99
Income Tax	0.04	0
Net Income	-28.97	-18.99
Shares Outstanding (Basic)	24	19
Shares Outstanding (Diluted)	24	19
Shares Change	25.21%	-
EPS (Basic)	-1.17	-0.96
EPS (Diluted)	-1.17	-0.96
Free Cash Flow	-20.76	-14.63
Free Cash Flow Per Share	-0.86	-0.76
EBITDA	-27.6	-17.86
Depreciation & Amortization	0.16	0.15
EBIT	-27.76	-18.01

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).